Early diagnosis and treatment: The goal of hepatitis C screening

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Selvapatt, Nowlan ^a   Brown, Ashley ^a   Thursz, Mark ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; LEDIPASVIR; SOFOSBUVIR;

CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HEALTH PROGRAM; HEPATITIS C; HUMAN; INFECTION RISK; LETTER; MEDICAL SERVICE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; UNSPECIFIED SIDE EFFECT; MASS SCREENING; PROCEDURES;

HEPATITIS C; HUMANS; MASS SCREENING;

EID: 84924109119     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h635     Document Type: Letter

References (5)

1. Koretz RL, Lin KW, Ioannidis JPA, Lenzer J. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809. (13 January.)
2. Health Protection Agency. Hepatitis C in the UK 2012 report. www.yhln.org.uk/data/documents/2013/HPA%20%282012%29%20Hepatitis%20C%20in%20the%20UK.pdf.
3. McEwan P, Ward T, Yuan Y., Kim R, L'italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013;58:54-64.
4. Hill A, Saleem J, Heath K.A., Simmons B. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23 309 patients with hepatitis C infection. American Association for the Study of Liver Diseases (AASLD) liver meeting, Boston, November 7-11, 2014. Abstract 44.
5. Daltro-Oliveira R., Morais de Jesus M, Pettersen KM, Parana R, Quarantini LC. Impact of sustained virologic response on quality of life in chronic HCV carriers. Ann Hepatol 2013;12:399-407.